Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the sale, the chief executive officer directly owned 8,808,533 shares of the company’s stock, valued at approximately $411,358,491.10. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Down 1.6%

NASDAQ TEM traded down $0.82 on Friday, reaching $50.47. The company had a trading volume of 11,745,909 shares, compared to its average volume of 5,693,381. The firm has a market capitalization of $9.06 billion, a PE ratio of -29.34 and a beta of 3.99. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The firm has a 50-day moving average of $48.69 and a 200-day moving average of $58.25. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.Tempus AI’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.24) EPS. On average, equities research analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Large investors have recently added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new position in Tempus AI during the third quarter worth $26,000. Los Angeles Capital Management LLC bought a new position in Tempus AI during the fourth quarter worth $27,000. Harvest Fund Management Co. Ltd bought a new position in Tempus AI during the third quarter worth $38,000. Tsfg LLC lifted its stake in Tempus AI by 1,515.2% during the third quarter. Tsfg LLC now owns 533 shares of the company’s stock worth $43,000 after purchasing an additional 500 shares during the last quarter. Finally, Cloud Capital Management LLC acquired a new stake in Tempus AI in the third quarter worth $44,000. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TEM has been the subject of several research analyst reports. Mizuho initiated coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price for the company. Jefferies Financial Group initiated coverage on Tempus AI in a research note on Monday, April 13th. They set an “underperform” rating and a $35.00 target price for the company. JPMorgan Chase & Co. reduced their target price on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Wednesday, March 11th. Finally, Stifel Nicolaus set a $60.00 target price on Tempus AI in a research note on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.